12/20
01:37 pm
rlay
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]
Medium
Report
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade [Yahoo! Finance]
12/12
09:34 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $21.00 price target on the stock.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $21.00 price target on the stock.
12/11
06:17 am
rlay
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival [Yahoo! Finance]
Medium
Report
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival [Yahoo! Finance]
12/11
06:00 am
rlay
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
High
Report
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
12/9
04:10 pm
rlay
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]
Medium
Report
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium [Yahoo! Finance]
12/9
04:05 pm
rlay
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Medium
Report
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
12/5
08:02 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at Leerink Partners from $19.00 to $18.00. They now have an "outperform" rating on the stock.
Medium
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at Leerink Partners from $19.00 to $18.00. They now have an "outperform" rating on the stock.
12/4
08:09 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at HC Wainwright from $20.00 to $16.00. They now have a "buy" rating on the stock.
Neutral
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target lowered by analysts at HC Wainwright from $20.00 to $16.00. They now have a "buy" rating on the stock.
12/3
08:13 am
rlay
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors [Yahoo! Finance]
Medium
Report
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors [Yahoo! Finance]
12/3
08:01 am
rlay
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
High
Report
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
12/3
08:00 am
rlay
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
High
Report
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
11/19
10:51 am
rlay
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround [Yahoo! Finance]
Low
Report
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround [Yahoo! Finance]
11/8
02:32 pm
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $19.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its price target raised by analysts at HC Wainwright from $19.00 to $20.00. They now have a "buy" rating on the stock.
11/7
04:05 pm
rlay
Relay Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Relay Therapeutics to Participate in Upcoming Investor Conferences
11/6
04:22 pm
rlay
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]
Low
Report
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights [Yahoo! Finance]
11/6
04:05 pm
rlay
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
Low
Report
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
10/30
04:05 pm
rlay
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
Low
Report
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
10/28
10:21 am
rlay
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses [Yahoo! Finance]
Low
Report
Institutional owners may consider drastic measures as Relay Therapeutics, Inc.'s (NASDAQ:RLAY) recent US$67m drop adds to long-term losses [Yahoo! Finance]
10/14
08:41 am
rlay
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Relay Therapeutics, Inc. (NASDAQ: RLAY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.